122 related articles for article (PubMed ID: 35468166)
1. Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3.
PLOS ONE Editors
PLoS One; 2022; 17(4):e0267745. PubMed ID: 35468166
[No Abstract] [Full Text] [Related]
2. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.
Brand TM; Iida M; Luthar N; Wleklinski MJ; Starr MM; Wheeler DL
PLoS One; 2013; 8(8):e71518. PubMed ID: 23951180
[TBL] [Abstract][Full Text] [Related]
3. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
Menendez JA; Lupu R
Breast Cancer Res; 2007; 9(5):111. PubMed ID: 17983482
[TBL] [Abstract][Full Text] [Related]
4. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
[TBL] [Abstract][Full Text] [Related]
5. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
[TBL] [Abstract][Full Text] [Related]
7. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Li X; Lau AYT; Ng ASN; Aldehaiman A; Zhou Y; Ng PKS; Arold ST; Cheung LWT
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507989
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Jura N; Shan Y; Cao X; Shaw DE; Kuriyan J
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21608-13. PubMed ID: 20007378
[TBL] [Abstract][Full Text] [Related]
10. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
11. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Lyu H; Han A; Polsdofer E; Liu S; Liu B
Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
[TBL] [Abstract][Full Text] [Related]
12. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.
Choi BK; Cai X; Yuan B; Huang Z; Fan X; Deng H; Zhang N; An Z
Protein Cell; 2012 Oct; 3(10):781-9. PubMed ID: 22983903
[TBL] [Abstract][Full Text] [Related]
13. Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases.
Keppel TR; Sarpong K; Murray EM; Monsey J; Zhu J; Bose R
J Biol Chem; 2017 Jan; 292(2):597-610. PubMed ID: 27872189
[TBL] [Abstract][Full Text] [Related]
14. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
Kol A; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Lamberts LE; Bensch F; de Vries EG; Schröder CP
Pharmacol Ther; 2014 Jul; 143(1):1-11. PubMed ID: 24513440
[TBL] [Abstract][Full Text] [Related]
15. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Amin DN; Campbell MR; Moasser MM
Semin Cell Dev Biol; 2010 Dec; 21(9):944-50. PubMed ID: 20816829
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma.
van der Horst EH; Weber I; Ullrich A
Int J Cancer; 2005 Feb; 113(5):689-98. PubMed ID: 15499613
[TBL] [Abstract][Full Text] [Related]
17. MNAR functionally interacts with both NH2- and COOH-terminal GR domains to modulate transactivation.
Kayahara M; Ohanian J; Ohanian V; Berry A; Vadlamudi R; Ray DW
Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1047-55. PubMed ID: 18682536
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
Umelo I; Noeparast A; Chen G; Renard M; Geers C; Vansteenkiste J; Giron P; De Wever O; Teugels E; De Grève J
Oncotarget; 2016 Jan; 7(3):3068-83. PubMed ID: 26689995
[TBL] [Abstract][Full Text] [Related]
19. The Radiolabeled HER3 Targeting Molecules for Tumor Imaging.
Molavipordanjani S; Hosseinimehr SJ
Iran J Pharm Res; 2021; 20(1):141-152. PubMed ID: 34400948
[TBL] [Abstract][Full Text] [Related]
20. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
Shankaran H; Zhang Y; Tan Y; Resat H
PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
